Favorable Outcome of COVID-19 Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination

J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e1045-e1046. doi: 10.1097/MPH.0000000000002099.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • B7-H1 Antigen / antagonists & inhibitors*
  • COVID-19 / complications*
  • COVID-19 / transmission
  • COVID-19 / virology
  • CTLA-4 Antigen / antagonists & inhibitors*
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Male
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy*
  • Neoplasms / virology
  • Prognosis
  • SARS-CoV-2 / isolation & purification*

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immune Checkpoint Inhibitors